NCT05995249View on ClinicalTrials.gov

A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

August 11, 2023

Primary Completion Date

December 18, 2023

Study Completion Date

December 31, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

TAK-279

TAK-279 capsules

DRUG

Erythromycin

Erythromycin tablets

DRUG

Phenytoin

Phenytoin capsules

DRUG

Efavirenz

Efavirenz tablets

Trial Locations (1)

85283

Celerion - Tempe, AZ Site, Tempe

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY